NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
SWOG Cancer Research Network
Trans Tasman Radiation Oncology Group
Sun Yat-sen University
Swiss Cancer Institute
Bristol-Myers Squibb
Centre Francois Baclesse
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
International Atomic Energy Agency
National Cancer Center, Korea